Targeting B-cell maturation antigen in multiple myeloma

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Multiple myeloma (MM) recurrence necessitates novel immunotherapies.
• B-cell maturation antigen (BCMA) is a highly selective target on malignant plasma cells.
• BCMA-targeted therapies offer a promising avenue for MM treatment.

Purpose of the Study:

• To review BCMA biology and its relevance in multiple myeloma.
• To highlight the clinical development of novel anti-BCMA immunotherapies.
• To discuss ongoing clinical trials for BCMA-targeted treatments in MM.

Main Methods:

• Review of BCMA-related biological mechanisms.
• Highlighting the development of an afucosylated anti-BCMA monoclonal antibody (GSK2857916) with a cytotoxic payload.
• Discussion of chimeric antigen receptor (CAR) T-cell therapy targeting BCMA.

Main Results:

• BCMA is a validated target for MM therapy.
• Afucosylated anti-BCMA antibody-drug conjugates demonstrate potential efficacy.
• BCMA-targeted CAR T-cells may induce durable anti-MM responses.

Conclusions:

• BCMA-targeted immunotherapies, including antibody-drug conjugates and CAR T-cells, represent a significant advancement in MM treatment.
• Ongoing clinical trials are evaluating the safety and efficacy of these novel approaches.
• These therapies hold promise for patients with relapsed and refractory multiple myeloma.